Insights

Cortado Ventures invests in Cadenza Bio

CorriXR Therapeutics is the first spinout of ChristianaCare, a large Delaware-based healthcare system

Let’s look back at 2023 for VC and our firm to set the stage for an exciting 2024

Preclinical biotechnology company initially focusing on therapeutic drug development to promote remyelination in Multiple Sclerosis OKLAHOMA CITY, Dec. 14, 2023 /PRNewswire/ -- Cadenza Bio, Inc. (Cadenza), a privately-held biotechnology company focused on developing...

Our General Partner Mike Moradi articulates our commitment to Moat Biotechnology.

FOR IMMEDIATE RELEASE Oct. 11, 2023 Contact: Anthony Triana atriana@saxum.com (Direct) 405.818.0791 Cortado Ventures Invests in Teren, Inc.: Advancing Data-Driven Solutions for Climate and Terrain Risk Assessment OKLAHOMA CITY – Cortado Ventures, an early-stage...

  AltAssets: Hefty exits help Cortado Ventures score huge fund size increase for sophomore raise Wall Street Journal VC Pro: VC Daily: What the New IPOs Mean for Late-Stage Market; Instacart Pops StrictlyVC: Musk gets probed, Neuralink searches for recruits, and...

Midcontinent VC firm brings total AUM to over $110M in less than three years; four-times increase from initial Fund I